Tobacco-Alternatives Market Remains Strong Despite Recent Headwinds

In recent months health regulators made significant moves to reshape the tobacco industry. Traditional cigarette companies continue to face significant FDA headwinds, while non-traditional tobacco products and smoking cessation products are facing less scrutiny. The Bedford Report examines investing opportunities in non-traditional tobacco and smoking cessation aids and provides stock research on Star Scientific, Inc.

There are many cigarette compnaies like RJ Reynolds , producer of Winston cigarettes or Altria Group , producer of Chesterfield cigarettes who would like to chnage some regulations about cigarette production.

David Howard, director of communications at Reynolds America, Inc. is optimistic that the market for dissolvable tobacco lozenges is growing. "These products provide smokers with an option to enjoy the pleasure of nicotine without bothering others," Howard said. "No secondhand smoke. No spitting. No cigarette butt." The tobacco industry believes these products contain far fewer cancer causing chemicals, and are a "harm reduction" strategy that could help people turn to less risky tobacco habits or eventually quit smoking.

The Bedford Report releases equity research on the smoking cessation sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Star Scientific engages in the development, implementation, and licensing of tobacco curing technology that prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke. The company is also involved in the manufacture, sale, marketing, and development of very low-TSNA dissolvable smokeless tobacco products, including ARIVA compressed powdered tobacco, cigalett pieces, STONEWALL Hard Snuff, and risk tobacco products.

Nabi Biopharmaceuticals is currently developing "NicVAX," an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. Unfortunately for Nabi, the company recently said that NicVAX failed to meet the primary endpoint in a Phase III trial. Raafat Fahim, president and chief executive of the Rockville, Maryland-based company said, "We are in the process of assessing the reasons for these unexpected data, as we await the results of the second Phase III trial."

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks